1010	Efavirenz	b3e740ad-46d9-48f5-85ab-7c319919ceb1
1028	Analgesics:	b3e740ad-46d9-48f5-85ab-7c319919ceb1
1064	Itraconazole	b3e740ad-46d9-48f5-85ab-7c319919ceb1
1055	Antifungals:	b3e740ad-46d9-48f5-85ab-7c319919ceb1
1002	?Nelfinavir M8 Metabolite?Nelfinavir Cmin	b3e740ad-46d9-48f5-85ab-7c319919ceb1
1049	Rifampin	b3e740ad-46d9-48f5-85ab-7c319919ceb1
1082	"Motility agents:
                              Cisapride"	b3e740ad-46d9-48f5-85ab-7c319919ceb1
995	Indinavir	b3e740ad-46d9-48f5-85ab-7c319919ceb1
988	Do not co-administer nevirapine with atazanavir because nevirapine substantially decreases atazanavir exposure and there is a potential risk for nevirapine-associated toxicity due to increased nevirapine exposures.	b3e740ad-46d9-48f5-85ab-7c319919ceb1
1088	Oral contraceptives:	b3e740ad-46d9-48f5-85ab-7c319919ceb1
1041	? Clarithromycin? 14-OH clarithromycin	b3e740ad-46d9-48f5-85ab-7c319919ceb1
1075	Appropriate doses for this combination have not been established.	b3e740ad-46d9-48f5-85ab-7c319919ceb1
980	Drug Name	b3e740ad-46d9-48f5-85ab-7c319919ceb1
1015	Plasma concentrations may be altered. Nevirapine should not be coadministered with another NNRTI as this combination has not been shown to be beneficial.	b3e740ad-46d9-48f5-85ab-7c319919ceb1
1033	Methadone levels were decreased; increased dosages may be required to prevent symptoms of opiate withdrawal. Methadone-maintained patients beginning nevirapine therapy should be monitored for evidence of withdrawal and methadone dose should be adjusted accordingly.	b3e740ad-46d9-48f5-85ab-7c319919ceb1
1068	Plasma concentrations may be increase.	b3e740ad-46d9-48f5-85ab-7c319919ceb1
1006	The appropriate doses of the combination of nevirapine and saquinavir/ritonavir with respect to safety and efficacy have not been established.	b3e740ad-46d9-48f5-85ab-7c319919ceb1
1023	Plasma concentrations of telaprevir may be decreased due to induction of CYP3A4  by nevirapine and plasma concentrations of nevirapine may be increased due to inhibition of CYP3A4 by telaprevir.	b3e740ad-46d9-48f5-85ab-7c319919ceb1
1061	Ketoconazole	b3e740ad-46d9-48f5-85ab-7c319919ceb1
1053	Plasma concentrations of nevirapine and the anticonvulsant may be decreased.	b3e740ad-46d9-48f5-85ab-7c319919ceb1
999	?Lopinavir	b3e740ad-46d9-48f5-85ab-7c319919ceb1
1046	Rifabutin	b3e740ad-46d9-48f5-85ab-7c319919ceb1
1079	"Immunosuppressants:
                              Cyclosporine, tacrolimus, sirolimus"	b3e740ad-46d9-48f5-85ab-7c319919ceb1
992	Fosamprenavir/Ritonavir	b3e740ad-46d9-48f5-85ab-7c319919ceb1
983	HIV Antiviral Agents: Protease Inhibitors (PIs)	b3e740ad-46d9-48f5-85ab-7c319919ceb1
1086	Plasma concentrations may be decreased.	b3e740ad-46d9-48f5-85ab-7c319919ceb1
1038	Plasma concentrations may be decreased.	b3e740ad-46d9-48f5-85ab-7c319919ceb1
1072	Appropriate doses for these combinations have not been established.	b3e740ad-46d9-48f5-85ab-7c319919ceb1
1011	? Efavirenz	b3e740ad-46d9-48f5-85ab-7c319919ceb1
1065	? Itraconazole	b3e740ad-46d9-48f5-85ab-7c319919ceb1
1020	Plasma concentrations of boceprevir may be decreased due to induction of CYP3A4/5 by nevirapine.	b3e740ad-46d9-48f5-85ab-7c319919ceb1
1058	Fluconazole	b3e740ad-46d9-48f5-85ab-7c319919ceb1
1003	The appropriate doses of the combination of nevirapine and nelfinavir with respect to safety and efficacy have not been established.	b3e740ad-46d9-48f5-85ab-7c319919ceb1
1050	? Nevirapine	b3e740ad-46d9-48f5-85ab-7c319919ceb1
1083	Plasma concentrations may be decreased.	b3e740ad-46d9-48f5-85ab-7c319919ceb1
996	? Indinavir	b3e740ad-46d9-48f5-85ab-7c319919ceb1
1076	"Ergot alkaloids:
                              Ergotamine"	b3e740ad-46d9-48f5-85ab-7c319919ceb1
989	Fosamprenavir	b3e740ad-46d9-48f5-85ab-7c319919ceb1
1091	Ethinyl estradiol and Norethindrone	b3e740ad-46d9-48f5-85ab-7c319919ceb1
1042	Clarithromycin exposure was significantly decreased by nevirapine; however, 14-OH metabolite concentrations were increased. Because clarithromycin active metabolite has reduced activity against Mycobacterium avium-intracellulare complex, overall activity against this pathogen may be altered. Alternatives to clarithromycin, such as azithromycin, should be considered.	b3e740ad-46d9-48f5-85ab-7c319919ceb1
981	Effect on Concentration of Nevirapine or Concomitant Drug	b3e740ad-46d9-48f5-85ab-7c319919ceb1
1016	Hepatitis C Antiviral Agents	b3e740ad-46d9-48f5-85ab-7c319919ceb1
1034	Antiarrhythmics:	b3e740ad-46d9-48f5-85ab-7c319919ceb1
1069	Potential effect on anticoagulation. Monitoring of anticoagulation levels is recommended.	b3e740ad-46d9-48f5-85ab-7c319919ceb1
1007	HIV Antiviral Agents: Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs)	b3e740ad-46d9-48f5-85ab-7c319919ceb1
1024	Nevirapine and telaprevir should not be coadministered because changes in plasma concentrations of nevirapine, telaprevir, or both may result in a reduction in telaprevir efficacy or an increase in nevirapine-associated adverse events.	b3e740ad-46d9-48f5-85ab-7c319919ceb1
1062	? Ketoconazole	b3e740ad-46d9-48f5-85ab-7c319919ceb1
1054	Use with caution and monitor virologic response and levels of anticonvulsants.	b3e740ad-46d9-48f5-85ab-7c319919ceb1
1000	"Dosing in adult patients:
                              A dose adjustment of lopinavir/ritonavir to 500/125 mg tablets twice daily or 533/133 mg (6.5 mL) oral solution twice daily is recommended when used in combination with nevirapine. Neither lopinavir/ritonavir tablets nor oral solution should be administered once daily in combination with nevirapine.
                              Dosing in pediatric patients:
                              Please refer to the KaletraÂ® prescribing information for dosing recommendations based on body surface area and body weight. Neither lopinavir/ritonavir tablets nor oral solution should be administered once daily in combination with nevirapine."	b3e740ad-46d9-48f5-85ab-7c319919ceb1
1047	? Rifabutin	b3e740ad-46d9-48f5-85ab-7c319919ceb1
1080	Plasma concentrations may be decreased.	b3e740ad-46d9-48f5-85ab-7c319919ceb1
993	"? Amprenavir
                              ? Nevirapine"	b3e740ad-46d9-48f5-85ab-7c319919ceb1
986	Atazanavir/RitonavirThe interaction between Nevirapine and the drug was evaluated in a clinical study. All other drug interactions shown are predicted.	b3e740ad-46d9-48f5-85ab-7c319919ceb1
1087	Appropriate doses for this combinations have not been established.	b3e740ad-46d9-48f5-85ab-7c319919ceb1
1039	Appropriate doses for this combination have not been established.	b3e740ad-46d9-48f5-85ab-7c319919ceb1
1073	"Cancer chemotherapy:
                              Cyclophosphamide"	b3e740ad-46d9-48f5-85ab-7c319919ceb1
1012	The appropriate doses of these combinations with respect to safety and efficacy have not been established.	b3e740ad-46d9-48f5-85ab-7c319919ceb1
1031	Methadone	b3e740ad-46d9-48f5-85ab-7c319919ceb1
1066	Nevirapine and itraconazole should not be administered concomitantly due to potential decreases in itraconazole plasma concentrations that may reduce efficacy of the drug.	b3e740ad-46d9-48f5-85ab-7c319919ceb1
1021	Nevirapine and boceprevir should not be coadministered because decreases in boceprevir plasma concentrations may result in a reduction in efficacy.	b3e740ad-46d9-48f5-85ab-7c319919ceb1
1059	?Nevirapine	b3e740ad-46d9-48f5-85ab-7c319919ceb1
1004	Saquinavir/ritonavir	b3e740ad-46d9-48f5-85ab-7c319919ceb1
1051	Nevirapine and rifampin should not be administered concomitantly because decreases in nevirapine plasma concentrations may reduce the efficacy of the drug. Physicians needing to treat patients co-infected with tuberculosis and using a nevirapine-containing regimen may use rifabutin instead.	b3e740ad-46d9-48f5-85ab-7c319919ceb1
1084	Appropriate doses for this combinations have not been established.	b3e740ad-46d9-48f5-85ab-7c319919ceb1
997	The appropriate doses of this combination of indinavir and nevirapine with respect to efficacy and safety have not been established.	b3e740ad-46d9-48f5-85ab-7c319919ceb1
1043	Antibiotics:	b3e740ad-46d9-48f5-85ab-7c319919ceb1
1077	Plasma concentrations may be decreased.	b3e740ad-46d9-48f5-85ab-7c319919ceb1
990	? Amprenavir? Nevirapine	b3e740ad-46d9-48f5-85ab-7c319919ceb1
1092	? Ethinyl estradiol? Norethindrone	b3e740ad-46d9-48f5-85ab-7c319919ceb1
982	Clinical Comment	b3e740ad-46d9-48f5-85ab-7c319919ceb1
1070	"Calcium channel blockers:
                              Diltiazem, nifedipine, verapamil"	b3e740ad-46d9-48f5-85ab-7c319919ceb1
1025	Other Agents	b3e740ad-46d9-48f5-85ab-7c319919ceb1
1063	Nevirapine and ketoconazole should not be administered concomitantly because decreases in ketoconazole plasma concentrations may reduce the efficacy of the drug.	b3e740ad-46d9-48f5-85ab-7c319919ceb1
1001	Nelfinavir	b3e740ad-46d9-48f5-85ab-7c319919ceb1
1048	Rifabutin and its metabolite concentrations were moderately increased. Due to high intersubject variability, however, some patients may experience large increases in rifabutin exposure and may be at higher risk for rifabutin toxicity. Therefore, caution should be used in concomitant administration.	b3e740ad-46d9-48f5-85ab-7c319919ceb1
1081	Appropriate doses for these combinations have not been established.	b3e740ad-46d9-48f5-85ab-7c319919ceb1
994	No dosing adjustments are required when nevirapine is co-administered with 700/100 mg of fosamprenavir/ritonavir twice daily. The combination of nevirapine administered with fosamprenavir/ritonavir once daily has not been studied.	b3e740ad-46d9-48f5-85ab-7c319919ceb1
987	? Atazanavir? Nevirapine	b3e740ad-46d9-48f5-85ab-7c319919ceb1
1040	"Antibiotics:
                              Clarithromycin"	b3e740ad-46d9-48f5-85ab-7c319919ceb1
1074	Plasma concentrations may be decreased.	b3e740ad-46d9-48f5-85ab-7c319919ceb1
1013	DelavirdineEtravirineRilpivirine	b3e740ad-46d9-48f5-85ab-7c319919ceb1
1032	? Methadone	b3e740ad-46d9-48f5-85ab-7c319919ceb1
1067	"Antithrombotics:
                              Warfarin"	b3e740ad-46d9-48f5-85ab-7c319919ceb1
1022	Telaprevir	b3e740ad-46d9-48f5-85ab-7c319919ceb1
1060	Because of the risk of increased exposure to nevirapine, caution should be used in concomitant administration, and patients should be monitored closely for nevirapine-associated adverse events.	b3e740ad-46d9-48f5-85ab-7c319919ceb1
1005	The interaction between nevirapine and saquinavir/ritonavir has not been evaluated	b3e740ad-46d9-48f5-85ab-7c319919ceb1
1052	"Anticonvulsants:
                              Carbamazepine, clonazepam, ethosuximide"	b3e740ad-46d9-48f5-85ab-7c319919ceb1
1085	"Opiate agonists:
                              Fentanyl"	b3e740ad-46d9-48f5-85ab-7c319919ceb1
998	Lopinavir/Ritonavir	b3e740ad-46d9-48f5-85ab-7c319919ceb1
1078	Appropriate doses for this combination have not been established.	b3e740ad-46d9-48f5-85ab-7c319919ceb1
991	Co-administration of nevirapine and fosamprenavir without ritonavir is not recommended.	b3e740ad-46d9-48f5-85ab-7c319919ceb1
1093	Oral contraceptives and other hormonal methods of birth control should not be used as the sole method of contraception in women taking nevirapine, since nevirapine may lower the plasma levels of these medications. An alternative or additional method of contraception is recommended.	b3e740ad-46d9-48f5-85ab-7c319919ceb1
1019	Boceprevir	b3e740ad-46d9-48f5-85ab-7c319919ceb1
1037	Amiodarone, disopyramide, lidocaine	b3e740ad-46d9-48f5-85ab-7c319919ceb1
1071	Plasma concentrations may be decreased.	b3e740ad-46d9-48f5-85ab-7c319919ceb1
